MRKR Filings — Marker Therapeutics, Inc. - FilingSpy
MRKR
Marker Therapeutics, Inc.
A Houston-based clinical-stage biotech company developing T cell-based immunotherapies for blood cancers and solid tumors. Its signature Multi-Antigen Recognizing (MAR) T cell therapy grows a patient's own tumor-fighting T cells in the lab without genetic modification, unlike engineered CAR-T treatments. The company's roots trace to research at Baylor College of Medicine, and its name comes from the tumor "markers" (antigens) its T cells are trained to spot. The current public company was formed in 2018 when TapImmune Inc. merged with the privately held Marker Therapeutics and took on its name.
Hoang Peter L.President and CEO, Director · 2 transactions
+45.3%
483.3Kas of Mar 2022
199.1K
—
—
Elms SteveDirector · 1 transaction
-89.7%
328.3K†as of Dec 2024
—
11.1K
—
Kim Anthony H.Chief Financial Officer · 2 transactions
—
114.4Kas of Mar 2022
150.5K
—
—
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +565.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.